2024-09-22 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis

**Company Overview:** Regeneron Pharmaceuticals Inc. is a leading biotechnology company that develops and commercializes life-transforming medicines for serious diseases.

**Performance Analysis:**

1. **Performance Comparison:**
    * **Cumulative Return (REGN):** 117.31%
    * **Cumulative Return (VOO):** 132.46%
    * **Relative Divergence:** -15.15% (55.66% relative to historical range)
    
    REGN has underperformed the S&P 500 (VOO) by 15.15% over the period considered.  This underperformance is relatively moderate compared to its historical range. 

2. **Recent Price Movement:**
    * **Closing Price:** $1145.03
    * **5-Day Moving Average:** $1147.38
    * **20-Day Moving Average:** $1163.53
    * **60-Day Moving Average:** $1117.09

    REGN's current price is below its 5-day, 20-day, and 60-day moving averages, suggesting a potential downward trend.

3. **Technical Indicators:**
    * **RSI:** 39.39 
    * **PPO:** -0.39
    * **Delta_Previous_Relative_Divergence:** -10.75 
    * **Expected Return:** 17.59%

    The RSI indicates that REGN is currently in oversold territory. The PPO indicates a downtrend.  The negative Delta_Previous_Relative_Divergence suggests a recent decline in the stock's relative performance.  The expected return of 17.59% is based on the current market conditions and past performance.

4. **Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | $3.55B |
| 2024-05-02 | 6.7 | $3.15B |
| 2023-11-02 | 9.48 | $3.36B |
| 2023-08-03 | 9.05 | $3.16B |
| 2024-08-01 | 9.05 | $3.16B |

* **Most Recent Earnings:** The latest earnings report for 2024-08-01 showed an EPS of 13.25 and revenue of $3.55B. While specific analyst expectations are not provided, the company has consistently exceeded revenue expectations in recent quarters.

**Overall Analysis:**

REGN has underperformed the S&P 500 in recent times, though this underperformance is moderate compared to its historical range.  Technical indicators suggest a potential downward trend in the short term.  However, the company's recent earnings have been strong, and the expected return remains positive.  Investors should consider these factors when making investment decisions.
